RxDoctor Payments Data

Luke Evans, MD

Gastroenterology · Littleton, CONPI 1205822707

Payments from drug & device makers

$9,956in general payments, 2019–2025

Across 463 payments — averaging $21.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$856
  • Takeda Pharmaceuticals U.S.A., Inc.$822
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$817
  • Inari Medical, Inc.$785
  • Gilead$671
  • plus $3K from 33 others

What the payments were for

  • Speaking & faculty fees$631%
  • Travel & lodging$7858%
  • Food & beverage$8,67787%
  • Education$4324%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,956 in reported general payments places this provider in the 75th percentile of 304 gastroenterology providers in Colorado.

See all gastroenterology providers in Colorado

Medicare billing

Part B allowed, 2024
$104,836
Medicare patients
283
Services billed
2,136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab46$1,303,776
Humira PenAdalimumab25$268,311
CreonLipase/Protease/Amylase13$70,590
XifaxanRifaximin11$34,927
ViberziEluxadoline16$34,689
Dexlansoprazole DrDexlansoprazole15$5,934
Omeprazole222$4,255
Mesalamine25$2,767
Budesonide DrBudesonide11$1,929
Pantoprazole Sodium141$1,470
Kcl-D5w-0.45% NaclPotassium Chloride/D5-0.45nacl40$1,380
Esomeprazole Magnesium35$1,283
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl29$526
Dicyclomine Hcl11$426
Famotidine21$388

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$856$1,303,77646 claims
AbbVieCreon, Viberzi$2,629$105,27929 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$817$34,92711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 304 gastroenterology providers in Colorado.

Other gastroenterology in Littleton

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →